PLUS1
49.995
1.81 (3.75%)
1.81 (3.75%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Y mAbs Therapeutics Inc | YMAB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 1.81 | 3.75% | 49.995 | 12:30:31 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 48.56 | 47.87 | 50.567 | 48.19 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 49.89 | 50.10 | 0.21 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,468 | 168,214 | $ 49.13 | $ 8,263,808 | 174,213 | 14.16 - 55.36 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:30:31 | 25 | $ 49.995 | USD |
Y mAbs Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 2.03B | 40.51M | 30.41M | $ - | $ - | -2.31 | -15.50 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | -74.00k | 1.10% |
Y mAbs Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/25/2020 | 17:30 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/25/2020 | 17:02 | GlobeNewswire Inc. | FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the.. |
| 11/20/2020 | 16:16 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/19/2020 | 10:33 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/19/2020 | 09:00 | GlobeNewswire Inc. | Y-mAbs Announces Update on Omburtamab in DIPG |
| 11/17/2020 | 16:16 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/05/2020 | 17:51 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical YMAB Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 41.80 | 51.99 | 40.09 | 45.26 | 263,953 | 8.20 | 19.61% |
| 1 Month | 43.30 | 55.36 | 39.90 | 45.61 | 215,795 | 6.70 | 15.46% |
| 3 Months | 37.51 | 55.36 | 36.11 | 42.14 | 174,914 | 12.49 | 33.28% |
| 6 Months | 38.11 | 55.36 | 33.71 | 42.25 | 184,684 | 11.89 | 31.19% |
| 1 Year | 34.10 | 55.36 | 14.16 | 35.76 | 208,044 | 15.90 | 46.61% |
| 3 Years | 26.50 | 55.36 | 14.16 | 30.98 | 173,675 | 23.50 | 88.66% |
| 5 Years | 26.50 | 55.36 | 14.16 | 30.98 | 173,675 | 23.50 | 88.66% |
Y mAbs Therapeutics Description
| Y-mAbs Therapeutics Inc is a late-stage clinical biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Products developed by the company include naxitamab for the treatment of pediatric patients with relapsed or refractory and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system. |
